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INTRODUCTION
Overall situation
An “epidemic” in the use of opioids in the USA and 
other countries, including European ones, has been re-
ported in the last 15 years [1-6]. Several scientific and 
governmental  institutes bodies deal with this issue, in-
cluding the Atlanta CDC (Center of Disease Control) 
that detected an increased number of deaths due to opi-
oids use between 2014 and 2015 [7, 8]. One of the rea-
sons is that patients, who begin to take opioids for pain 
therapy after surgery  (postoperative analgesia),  may 
develop an “addiction” when the treatment becomes 
chronic [9], i.e. when it lasts for more than three months 
[10]. American scientific and governmental bodies, that 
analysed this issue, agreed upon the need to set up na-
tional and supranational registers including prescrip-
tion and consumption of opioids (which were difficult 
to establish in the USA) as well as the need for spe-
cific laws and guidelines regarding opioids prescriptions 
[11]. The main corrective actions were assisted by the 
ASIPP (American Society of Interventional Pain Physi-
cians) through the establishment of a national register 
of prescriptions (NASPER – National All Schedules 
Prescription Electronic Reporting Act), however with 
limitations that relegated it to single states in the US 
and not to the whole country [12]. From a regulatory 
point of view, ASIPP established collaborations with the 
Atlanta CDC, the NIDA (National Institute on Drug 
Abuse) and the FDA (Food and Drug Administration) 
in order to guarantee appropriate prescription by physi-
cians along with the promotion of a correct education in 
patients in treatment with opioids [13-15].
Risk of addiction
Based on several surveys (principally carried out in 
the USA), the risk of addiction seems to develop when 
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Abstract 
Background. An “epidemic use” of legal opioids in the USA and other countries has 
been reported in the last 15 years. We have analysed the database of the Italian Ministry 
of Health regarding the prescription of opioids for pain management to verify the trend 
of opioids uses in Italy.
Methods. The amount of opioids prescribed for every single Italian patient in 2013 was 
anonymously recorded and transformed in daily MED (morphine equivalent dose). 
We considered every monthly percentage increase of MED during the entire period of 
chronic therapy for each patient.
Results. Classes of dosage increase for all patients in chronic therapy, distinguished be-
tween cancer and non-cancer ones, were created. We deduce that decreases or increases 
of small proportions prevailed in the observation period.
Conclusions. The opioids “plague” that is striking the USA is not registered in Italy dur-
ing the observation period. The reasons might be due to the innovative and effective law 
38/2010 and a health care system able to guarantee appropriate prescriptions for major 
analgesics.
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prescribed doses exceed 40-50 mg MED (Morphine 
Equivalent Dose in milligrams) a day [11]. Another 
parameter as the average pro capita a year being 144 
MED in Italy, is far below the average of 693 MED a 
year in the USA and other European and non-Europe-
an countries (taking in consideration the six most com-
mon opioids) [11].
The aim of the study
This study aims to assess if there is a risk of addiction 
for Italian patients suffering from chronic cancer and 
non-cancer pain, who undergo chronic pain therapy 
with opioids, based on a previous Italian study that de-
fined which patients are to be considered chronic opi-
oids users [16]. In that paper, Authors analysed a yearly 
Italian opioids prescription database with the aim to de-
termine, with a specific algorithm, chronic cancer and 
non-cancer opioids users. With this in mind, we began 
analysing the same previous database of Italian Minis-
try of Health  [16] regarding the prescription of opioids 
for pain management, to determine potentially addic-
tive behaviours.
METHODS
The population of the study
All opioid prescriptions covered by the  National 
Health  System in 2013 were collected anonymously. 
Patients with at least one prescription of an opioid a 
month for three consecutive months and/or six non-
consecutive months in the reporting period (from 1 
January to 31 December) were considered chronic. 
Cancer patients were those who entitled to exemption 
code 048 (“malignant neoplastic disease”) or the ones 
who were given ROOs (Rapid Onset Opioids; drugs 
that can only be prescribed to cancer patients in Italy).
Opioids requirements
Analysing the encrypted identification codes of the 
patients, we examined the attitude of prescriptions for 
each cancer and non-cancer patient. The amount of 
required opiates for any patient was transformed into 
daily MED.  The MED is calculated using a specific 
conversion tool to pass from any opioid prescribed to 
morphine equivalent dosage [17].We excluded the first 
three months of therapy, as a period of dosage adjust-
ment. Starting from the fourth month (our baseline), 
we considered every monthly percentage increase of 
MED during the entire period of chronic therapy.
Statistical analysis
The patients were subdivided into classes of the per-
centage increase or decrease from the baseline value. 
We compared the results of cancer and non-cancer pa-
tients through two unpaired Student  t-test samples. P 
values < 0.05 were considered significant.
RESULTS
Based on previous study referring to the same data-
base [16] in Italy 422 542 patients were found to be on 
chronic opioid therapy in 2013, of which 52 581 were 
cancer  patients (with ticket exemption code number 
048 – “malignant neoplastic disease”).  The  following 
specific analysis of the database shows in Table 1 the 
classes of mean dosage increase/decrease for all the pa-
tients considered as a unique cluster on chronic therapy 
and then distinguishes between cancer and non-cancer 
ones. Figure 1 shows the numbers of total patients, 
cancer and non-cancer ones, in each incremental class. 
Figure 2 represents the percentage increase in MED of 
opioids for all patients, cancer and non-cancer ones. 
Looking at both figures, we deduce that small propor-
tions of decrease or increase prevailed in the reporting 
period. Cancer patients had a greater percentage of in-
creases, although they were not statistically significant 
(p-value > 0.05). The mean MED for each patient is 
already described in a previous work [16].
DISCUSSION
Opioids increase rate
Our results did not show an excessive dosage in-
crease in patients on chronic therapy with opioids in 
Italy during the observational period (patients mainly 
had a decrease or only a modest increase in their dos-
age). Despite not having an international database to 
compare to, this probably means that the American 
opioid epidemic did not involve Italy. This situation 
could be due to the Italian law 38/2010 [18] which, 
for the first time in Europe and one of the first times 
in the world, regulated the clinical practice regarding 
opioid therapy for patients suffering from chronic pain. 
In particular, it facilitates opioid prescription when 
necessary, meanwhile creating a culture of knowledge 
for healthcare professionals and instruments of control 
Table 1
Opioids morphine equivalent dose (MED) increase rate in 
chronic pain patients
Classes of MED 
increase (%)
Total 
patients
Non-cancer 
patients
Cancer 
patients
<0 131 316 112 358 18 958
0-10 125 055 115108 9947
10-20 33 718 29 996 3722
20-30 29 070 25 127 3943
30-40 26 789 24 307 2482
40-50 31 014 27 077 3937
50-60 8366 6459 1907
60-70 9633 7769 1864
70-80 6802 5549 1253
80-90 4943 3699 1244
90-100 4436 3699 737
100-110 1690 1479 211
110-120 1521 1349 172
120-130 1309 1109 200
130-140 1309 1109 200
140-150 1014 739 275
150-200 2915 2219 696
>200 1642 809 833
Total 422 542 369 961 52 581
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Figure 1 
Number of patients in each class of percent increase in daily MED of opioids.
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Figure 2 
Percentage of patients in each incremental class of daily MED of opioids.
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in order to ensure a constant appropriate prescription. 
This seems to prevent the development of the phenom-
enon of addiction in chronic patients. Other prelimi-
nary studies [16] proved that daily MED prescribed 
to non-cancer patients (30,13 mg) are lower than the 
baseline values of 40-50 mg/day that are considered 
to cause addiction by the American scientific society 
[11]. A recent analysis published on Pain [9] indicated 
how the starting dosage for patients who would receive 
chronic therapy in some American analgesic treatment 
centres (55 mg/day that would increase to 83 mg/day) 
was higher than the average dosage observed in Italy. 
This difference may primarily be due to the Italian law 
38/2010 that created a “hub & spoke” organisation for 
the control and management of opioids, and secondly 
due to where the analysis took place in consideration 
that in the USA the analysis was done in specific anal-
gesic treatment centres.
Situation in Italy
In Italy all the prescriptions we considered, includ-
ing those from general practitioners who might tend to 
start with lower doses due to lack of experience in the 
field of pain care. Recently we also considered cancer 
patients with long survival as patients potentially sub-
ject to addiction on the heels of the American “plague”. 
The average dosage in daily MED in Italian patients 
(79.47 mg) was coherent with an other international 
analysis that reported an average of 80 mg/day [19] in 
cancer patients.
Risk of addiction
Our analysis showed that neither a risk of addiction 
nor an indication to limit opioid therapy in these pa-
tients seems to exist, being in accordance with recent 
publications [20]. 
CONCLUSIONS
The opioids “plague” that is striking the USA has not 
struck Italy. The reasons might be due to the innova-
tive and effective law 38/2010 together with a health 
care system able to guarantee appropriate prescriptions 
for major analgesics. Nevertheless, it might be useful 
to continue the ministerial monitoring carried out in 
2013, with the aim to identify any aberration in opioid 
prescriptions.
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